Cargando…
Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma
BACKGROUND: Our aim was to evaluate the feasibility and safety of isotoxic high-dose (iHD) stereotactic body radiation therapy (SBRT) in a total neoadjuvant sequence for the treatment of localized pancreatic adenocarcinoma. MATERIALS AND METHODS: Biopsy-proven borderline resectable/locally advanced...
Autores principales: | Bouchart, Christelle, Engelholm, Jean-Luc, Closset, Jean, Navez, Julie, Loi, Patrizia, Gökburun, Yeter, De Grez, Thierry, Mans, Laura, Hendlisz, Alain, Bali, Maria Antonietta, Eisendrath, Pierre, Van Gestel, Dirk, Hein, Matthieu, Moretti, Luigi, Van Laethem, Jean-Luc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529314/ https://www.ncbi.nlm.nih.gov/pubmed/34691244 http://dx.doi.org/10.1177/17588359211045860 |
Ejemplares similares
-
Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation
por: Manderlier, Martin, et al.
Publicado: (2022) -
EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score
por: Figueiredo, Mariana, et al.
Publicado: (2021) -
Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
por: Bouchart, Christelle, et al.
Publicado: (2020) -
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
por: Bouchart, Christelle, et al.
Publicado: (2023) -
What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?
por: Navez, Julie, et al.
Publicado: (2021)